BDBM494979 US10994015, Example 275

SMILES C[C@H](NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@@H](NC(=O)COCCOCCOCCOCCOCCOCC#Cc1cccc2CN([C@@H](C(=O)Nc3nccs3)c3cc(F)ccc3O)C(=O)c12)C(C)(C)C)c1ccc(cc1)-c1scnc1C

InChI Key InChIKey=BQCLGZPUYAFDOX-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 494979   

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Arvinas Operations

US Patent
LigandPNGBDBM494979(US10994015, Example 275)
Affinity DataIC50: 69nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Arvinas Operations

US Patent
LigandPNGBDBM494979(US10994015, Example 275)
Affinity DataIC50: 660nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Arvinas Operations

US Patent
LigandPNGBDBM494979(US10994015, Example 275)
Affinity DataIC50: 880nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Arvinas Operations

US Patent
LigandPNGBDBM494979(US10994015, Example 275)
Affinity DataIC50: 9.10E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent